F-ATP hydrolase inhibitors

WO2026024812A1PCT designated stage Publication Date: 2026-01-29LUCY THERAPEUTICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/038810
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-24
Filing Date
2025-07-23
Publication Date
2026-01-29

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000010_0001
    Figure IMGF000010_0001
Patent Text Reader

Abstract

The present disclosure provides substituted 2,3,4,5-tetrahydro-1H-benzo [e] [1,4] diazepin-l-yl compounds, pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, utilized in the manufacture of a medicament for the inhibition of F-ATP hydrolase and for treating diseases, disorders or conditions associated with F-ATP hydrolase, including Alzheimer's disease, Parkinson's Disease, amyotrophic lateral sclerosis, Friedreich's ataxia and cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Benzodiazepine derivatives

    US20030186969A1

  • Novel [1,4]benzodiazepines as vasopressin V2 receptor antagonists

    US20060116367A1

  • Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase

    WO2001081322A1

  • Novel f-atpase hydrolase inhibitors

    WO2024158698A1